4.3 Review

Acceptance, availability and feasibility of RTS, S/AS01 malaria vaccine: A review of literature

期刊

ASIAN PACIFIC JOURNAL OF TROPICAL MEDICINE
卷 16, 期 4, 页码 162-168

出版社

WOLTERS KLUWER MEDKNOW PUBLICATIONS
DOI: 10.4103/1995-7645.374354

关键词

RTS; S; AS01; Malaria; Plasmodium; Vaccine

向作者/读者索取更多资源

Malaria remains a serious infectious disease and is a leading cause of death among children in malaria endemic areas. Development of malaria vaccines has made significant progress in the last decade, with the RTS, S/AS01 malaria vaccine recommended for widespread use by the World Health Organization. However, acceptance of the vaccine is relatively low in middle-income countries, possibly due to lack of information. Careful consideration of each community's socio-cultural setting is necessary for the proper execution of the vaccination program.
Malaria remains the most serious infectious disease and is one of the leading causes of death among children in malaria endemic areas. The development of malaria vaccines has been underway since 1960s. Significant progress in the development of vaccine has been made in the last decade. On 6 October 2021, World Health Organization recommended widespread use of the RTS, S/AS01 malaria vaccine. The level of acceptance of RTS, S/AS01 malaria vaccine is relatively low in middle-income countries. This might be because of lack of information regarding vaccine implementation in such countries. The proper and efficient execution of the malaria vaccination program necessitates careful consideration of each community's socio-cultural setting. The most prominent RTS, S/AS01 vaccine trial was conducted from 2009 to 2011 in which eleven sites in seven African countries participated. Results of the trial, published in 2015, provided a promising advance in the development of a malaria vaccine for African children. As of 2019, large-scale pilot studies of the vaccine have been conducted in Ghana, Kenya, and Malawi, involving several hundreds of thousands of infants. The RTS, S/AS01 vaccine shows modest efficacy against malaria and has a feasible mode of administration. Although there is increased risk of meningitis, cerebral malaria, pneumonia, anemia, febrile convulsions and gastroenteritis, the vaccine still has a feasible mode of administration and high cost effectiveness and can be easily implemented in resource-limited settings.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.3
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据